Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies

Shots:

• Editas & BlueRock enter in to research collaboration to develop engineered cell therapies/ allogeneic pluripotent stem cell (PSC) lines by the combination of Editas’ CRISPR & BlueRock’s iPSC in oncology & neurology, cardiology and immunology respectively
• According to cross-licensing agreement, BlueRock to get non-exclusive & IPR rights for Editas Medicine’s CRISPR technology and Editas to get non-exclusive & IPR rights for BlueRock’s iPSC and cell differentiation technology. The companies will also receive development, regulatory and commercial milestones & royalties on global sales of products
• Editas’ CRISPR is a genome editing technology utilizes Cas9 or Cpf1 protein to repair broken genes. BlueRock’s iPSC is the basis of CELL+GENE platform used to replace damaged or degenerated tissue to restore or regenerate lost function

Click here to read full press release/ article | Ref: Editas Medicine | Image: PMLive